SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: keokalani'nui who wrote (883)10/9/2003 6:37:05 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
To all,
Simple and short!
Facts are clear. PII was failure from efficacy standpoint and from its purpose, selection of the PIII dose/regime.

Is 100 mg limit? Well, why they stopped at 800 mcg/kg in PI?

The future is twice-a week dosing, dose=? (but with improved formulation), imo.
Will see can VRTX improve Pralnacasan efficacy with higher dose?

Miljenko